NCT04154748 is a NA clinical trial of Argon Plasma Coagulation 90W power in Barretts Esophagus With Low Grade Dysplasia, sponsored by Maria Sklodowska-Curie National Research Institute of Oncology.

Who is sponsoring NCT04154748?

NCT04154748 is sponsored by Maria Sklodowska-Curie National Research Institute of Oncology.

What drugs are being tested in NCT04154748?

Interventions in NCT04154748: Argon Plasma Coagulation 90W power, Argon Plasma Coagulation 60W power, Omeprazole 120 mg, Omeprazole 40 mg.

What condition does NCT04154748 study?

NCT04154748 studies Barretts Esophagus With Low Grade Dysplasia.

Is NCT04154748 still recruiting?

NCT04154748 is currently completed. Last updated 19 November 2019.

Last reviewed 2019-11-19 · How we verify

NCT04154748

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Argon Plasma Coagulation for Barrett's Esophagus

Completed NA Last updated 19 November 2019

What this trial tests

NA trial testing Argon Plasma Coagulation 90W power in Barretts Esophagus With Low Grade Dysplasia in 71 participants. Completed in 5 July 2019.

Timeline

4 June 2002

Primary endpoint
10 February 2015

5 July 2019

Quick facts

Lead sponsor	Maria Sklodowska-Curie National Research Institute of Oncology
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	71
Start date	4 June 2002
Primary completion	10 February 2015
Estimated completion	5 July 2019

Drugs / interventions tested

Argon Plasma Coagulation 90W power
Argon Plasma Coagulation 60W power
Omeprazole 120 mg — full drug profile →
Omeprazole 40 mg — full drug profile →

Conditions studied

Barretts Esophagus With Low Grade Dysplasia — all drugs for Barretts Esophagus With Low Grade Dysplasia →

Sponsor

Maria Sklodowska-Curie National Research Institute of Oncology

Who can join

18 and older, any sex, with Barretts Esophagus With Low Grade Dysplasia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background and study aims. To evaluate the impact of power setting and proton pump inhibitor (PPI) dose on the efficacy and safety of argon plasma coagulation (APC) of Barrett's esophagus (BE) with low-grade dysplasia (LGD). Patients and methods. Investigator initiated, single-center, parallel-group randomized controlled trial (RCT) conducted in a tertiary referral center in Poland. Consecutive patients with BE and LGD were randomly assigned to APC with power set at 90 Watt (90W) or 60 Watt (60W) followed by 120 mg or 40 mg omeprazole for six weeks. The primary outcome of the study was the rate of complete (endoscopic and histologic) ablation of BE at six weeks. Secondary outcomes included safety and long-term efficacy (at two years and at the end of a long-term follow-up of over 4 years.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Maria Sklodowska-Curie National Research Institute of Oncology trials

Trials by the same sponsor.

NCT07216157 — NoSeal Trial: Comparing Sealants Versus No Sealant for Preventing CSF Leak After Endonasal Skull Base Surgery · NA · recruiting
NCT06472583 — Preoperative Immunotherapy Combined With Stereotactic Radiation Therapy Boost in the Treatment of HER2-negative Breast C · Phase 2 · recruiting
NCT05271162 — Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines · Phase 3 · recruiting
NCT06201078 — Stereotactic Re-irradiation of Local Recurrences of Prostate Cancer After Radiotherapy · Phase 2 · recruiting
NCT06128863 — Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tiss · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04154748 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Maria Sklodowska-Curie National Research Institute of Oncology
Last refreshed: 19 November 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04154748.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing